Bloodstream infections in patients given treatment with intravenous prostanoids
Bloodstream infections in patients given treatment with intravenous prostanoids
复制标题
DOI：
10.1086/529552
复制
发表时间：
2008-04-01
影响因子：
4.5
通讯作者：
Srinivasan, Arjun
中科院分区：
文献类型：
--
作者：
Kallen, Alexander J.;Lederman, Edith;Srinivasan, Arjun
目标。2006年9月，疾病控制和预防中心接到通知，在接受静脉注射前列腺素制剂的门诊病人中发生革兰氏阴性血液感染（BSI）病例。研究人员进行了一项调查，以确定该患者人群中前列腺素相关BSI的发生率和可能的感染危险因素。我们对2004年1月1日至2006年底接受静脉注射两种获批前列腺素（epoprostenol和treprostiil）中至少一种的患者进行了回顾性队列研究。对2个大型肺动脉高压中心进行了图表回顾，并对1个中心的感染控制实践进行了调查。224例患者接受静脉前列腺素治疗，研究期间共146093个治疗日。总体而言，每1000个治疗日有0.55例BSI和0.18例由革兰氏阴性菌引起的BSI。静脉注射treprostiil的患者BSI发生率高于静脉注射epoprostenol的患者（1.13 vs 0.42 BSI / 1000治疗天；），由革兰氏阴性菌引起的BSI发生率也是如此(0.81 vs 0.04 BSI / 1000治疗天
OBJECTIVE. In September 2006, the Centers for Disease Control and Prevention was notified of cases of gram-negative bloodstream infection (BSI) occurring among outpatients who received an intravenous formulation of the prostanoid treprostinil. An investigation was conducted to determine rates of prostanoid-associated BSI in this patient population and possible risk factors for infection.METHODS. We performed a retrospective cohort study of patients who had received intravenous formulations of at least 1 of the 2 approved prostanoids (epoprostenol and treprostinil) from January 1, 2004, through late 2006. Chart reviews were conducted at 2 large centers for pulmonary arterial hypertension, and a survey of infection control practices was conducted at 1 center.RESULTS. A total of 224 patients were given intravenous prostanoid treatment, corresponding to 146,093 treatment-days during the study period. Overall, there were 0.55 cases of BSI and 0.18 cases of BSI due to gram-negative organisms per 1,000 treatment-days. BSI rates were higher for patients who received intravenous treprostinil than for patients who received intravenous epoprostenol (1.13 vs. 0.42 BSIs per 1,000 treatment-days;), as were rates of BSI due to gram-negative organisms (0.81 vs. 0.04 BSIs per 1,000 treatment-days; P